Central nervous system disease
Active central nervous system (CNS) metastases.
Patients must not have known central nervous system metastasis or a history of central nervous system (CNS) metastases; patients with leptomeningeal disease are not eligible
Patients must not be known to have AML in the central nervous system (CNS)
Patients with known central nervous system (CNS) metastases are not eligible; Note: brain imaging is not an eligibility requirement
Central nervous system (CNS) status must be determined based on a sample obtained prior to the administration of any systemic or intrathecal chemotherapy, with the exception of steroid pretreatment
Patients with central nervous system (CNS) disease are not eligible
Central nervous system (CNS) metastases .
Subjects with inactive central nervous system (CNS) metastasis are eligible..
Known central nervous system (CNS) lymphoma
Known central nervous system (CNS) leukemia.
Medically apparent central nervous system lymphoma or leptomeningeal disease
Untreated or active central nervous system metastases
AML patients with active central nervous system (CNS) disease will be excluded.
Known untreated central nervous system metastases and/or carcinomatous meningitis
Patients with known symptomatic central nervous system metastases requiring steroids.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases;
Active extramedullary AML in testes or central nervous system (CNS)
Non-central nervous system (CNS) radiotherapy within 1 week prior to C1D1 of study therapy
Active or untreated central nervous system (CNS) metastases
Central nervous system lymphoma or leptomeningeal infiltration
History of central nervous system lymphoma (either primary or metastatic).
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Clinical evidence of active central nervous system leukemia;
History or evidence of uncontrollable central nervous system (CNS) disease
Participant must not have a known uncontrolled malignancy of the central nervous system.
Active, untreated central nervous system (CNS) metastasis
Subject has known current central nervous system (CNS) disease
Symptomatic and/or untreated central nervous system metastases
Symptomatic central nervous system metastases
Presence of any active central nervous system (CNS) disease at the time of evaluation (parenchymal or leptomeningeal)
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Known active central nervous system metastases and/or carcinomatous meningitis
Central nervous system (CNS) lymphoma or leptomeningeal infiltration
Known central nervous system (CNS) metastases and/or carcinomatous meningitis (includes past history or current metastasis)
Active central nervous system metastases
Known central nervous system lymphoma.
Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable
History of central nervous system metastasis
Known central nervous system (CNS) lymphoma
Active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system mass lesion
Has a history of primary central nervous system malignancy.
Participants with known untreated brain or other central nervous system metastases are excluded
Central nervous system metastases
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
Active central nervous system (CNS) disease at time of screening.
Participants who received prior non-central nervous system (CNS) directed palliative radiation therapy within 7 days of the date of study entry
Active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of central nervous system [CNS] metastases or spinal cord compression are eligible if they are clinically stable for at least 4 weeks before first dose of investigational product and do not require high-dose steroid treatment).
Have known central nervous system malignancy or metastasis.
Symptomatic central nervous system (CNS) malignancy or metastasis.
Has a known active central nervous system metastasis and/or carcinomatous meningitis.
History of seizure disorders or unstable central nervous system metastases
Known active central nervous system metastases and/or carcinomatous meningitis.
Patients with primary central nervous system (CNS) cancer.
Active central nervous system metastases and/or carcinomatous meningitis
Has known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
Have active central nervous system (CNS) leukemia
Any untreated central nervous system (CNS) lesion.
Active or untreated central nervous system (CNS) metastases
Current central nervous system (CNS) lymphoma or leptomeningeal infiltration.
Known central nervous system (CNS) lymphoma
Known central nervous system (CNS) lymphoma
Central nervous system (CNS) metastases (brain or leptomeningeal)
Symptomatic or untreated central nervous system (CNS) metastases
Symptomatic central nervous system (CNS) metastases.
Active central nervous system (CNS) disease.
Patient with a tumor metastasis in the central nervous system
Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Patients with untreated central nervous system metastases
Known central nervous system metastases
Known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis or known malignancy that progressed or required active treatment within the last 2 years
Known central nervous system lymphoma
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Presence of symptomatic or untreated central nervous system (CNS) metastases
Symptomatic and/or untreated central nervous system metastases
Central nervous system malignancy
Measurable disease according to RECIST v1.1 (must be outside central nervous system (CNS))
Active central nervous system (CNS) leukemia
Untreated central nervous system (CNS) metastases
Have symptomatic central nervous system malignancy or metastasis.
Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Known central nervous system (CNS) lymphoma
Central nervous system (CNS) tumors
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Untreated, symptomatic Central nervous system (CNS) metastases
Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
Central nervous system (CNS) disease
Active extramedullary AML in testes or central nervous system (CNS)
Symptomatic central nervous system metastasis (e.g., patients requiring increasing doses of steroids)
Active, uncontrolled central nervous system (CNS) disease including CNS leukemia
Uncontrolled central nervous system (CNS) metastases (previously treated with radiation and off steroids is acceptable)
Central nervous system (CNS) metastases or seizure disorder
Metastatic disease to the central nervous system
Presence of central nervous system (CNS) lymphoma
Patients with retinoblastoma protein (Rb1) positive recurrent, progressive or refractory central nervous system (CNS) tumors
PROCUREMENT EXCLUSION CRITERIA: Patients diagnosed with primary central nervous system (CNS) tumors
Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
Uncontrolled metastatic disease to the brain or central nervous system (CNS).
Patients with known central nervous system metastases, including lymphomatous meningitis
Central nervous system metastases, including lymphomatous meningitis
Without clinical signs of active central nervous system disease
Known central nervous system or visceral metastases
Have symptomatic central nervous system (CNS) malignancy (with the exception of medulloblastoma) or metastasis (screening not required).
Presence of active untreated central nervous system (CNS) leukemia
Presence of central nervous system (CNS) disease, which is symptomatic
Diagnosis of primary central nervous system lymphoma
Prior therapy for central nervous system (CNS) lymphoma\r\n* Steroids not an exclusion
TREATMENT WITH SJCAR19: Central nervous system (CNS)-3 disease with or without neurologic changes
EXCLUSION - PARTICIPANT: Participants with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Documented central nervous system metastases or liver metastasis
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Documented active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis;
Patients must not have evidence of active central nervous system (CNS) disease
Has known active (=growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; radiation or resected brain metastasis are acceptable if clinically stable
Evidence of > grade 1 central nervous system (CNS) hemorrhage on the baseline MRI scan.
Recurrent or refractory ALL limited to isolated testicular or isolated central nervous system (CNS) disease
Primary central nervous system malignancy
Active central nervous system (CNS) or extramedullary disease
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Leptomeningeal carcinomatosis or other central nervous system (CNS) metastases
Central nervous system (CNS) metastasis.
Presence of known central nervous system (CNS) leukemia.
Known central nervous system (CNS) lymphoma or leukemia
Known central nervous system malignancy. Note: Central nervous system imaging is only required in subjects with suspected central nervous system malignancy.
Active central nervous system metastases and/or leptomeningeal disease
Known central nervous system (CNS) lymphoma
Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable
Has radiographically detectable central nervous system metastases and/or carcinomatous meningitis as assessed by local site investigator at the time of diagnosis
Patients with history of prior central nervous system (CNS) metastasis must have been treated, must be asymptomatic, and must not have any of the following at the time of enrollment:
Untreated central nervous system (CNS) metastases
Patients with active central nervous system (CNS) leukemia eligible at the discretion of treating physician
Symptomatic central nervous system metastases
Uncontrolled central nervous system metastases
Active or untreated central nervous system (CNS) metastases Exclusions Related to Cardiovascular Disease
Patients/subjects with suspected or known central nervous system metastases unless adequately treated
Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.
Patients have a histologically or radiographically confirmed relapsed or refractory solid tumor or primary central nervous system (CNS) malignancy
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
Subjects with symptomatic central nervous system (CNS) disease which is not adequately controlled
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
Known untreated central nervous system metastases and/or carcinomatous meningitis.
Have central nervous system disease (CNS) as follows:
Poorly controlled or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis
Active central nervous system (CNS) disease
Presence of symptomatic or uncontrolled central nervous system or leptomeningeal metastases
Known primary central nervous system (CNS) malignancy
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis and/or has known active central nervous system (CNS) leukemia involvement
Known central nervous system (CNS) metastases and/or carcinomatous meningitis
Active, untreated central nervous system (CNS) metastases
Patients with active visceral, central nervous system, or any bone metastases melanoma (stage IVM1b or IVM1c)
History of central nervous system lymphoma (either primary or metastatic).
Patients with a history of central nervous system disease must have no clinical or radiological evidence of central nervous system (CNS) disease at the time of protocol enrollment and with CNS toxicity =< grade 2; patients with seizure disorders may be enrolled if seizures are well controlled
Presence of active and clinically relevant central nervous system (CNS) disorder;
Presence of active and clinically relevant Central Nervous System (CNS) disorder
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Central nervous system lymphoma, including lymphomatous meningitis
Patients with active and/or untreated central nervous system (CNS) lymphoma will not be eligible
Patients with active, uncontrolled central nervous system (CNS) leukemia will not be eligible
Active central nervous system (CNS) leukemia at time of treatment
Subjects with untreated central nervous system (CNS) metastases or carcinomatous meningitis are excluded
Presence of any significant central nervous system (CNS) or psychiatric disorder(s) that would hamper the patient's compliance;
Patients with known brain metastases, active infection, or untreated central nervous system (CNS) leukemia
Colorectal, hepatocellular, gallbladder, cholangiocarcinoma, neuroendocrine, melanomas, hematological and central nervous system (CNS) malignancies;
Active central nervous system (CNS) disease in patient with history of CNS malignancy.
Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI)
Have known central nervous system malignancy or metastasis.
Known central nervous system (CNS) leukemia
History of central nervous system lymphoma (either primary or metastatic).
Patients with isolated extramedullary disease or with known parenchymal central nervous system (CNS) disease
Patients with known active uncontrolled central nervous system (CNS) leukemia.
Patient has known active central nervous system metastases.
Active central nervous system (CNS) metastases.
Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease
Central nervous system (CNS) metastases: patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy and stable with no recurrent lesions for at least 3 months from the start of protocol therapy
Must not have suspected or known central nervous system metastases unless adequately treated
Subjects with symptomatic Central Nervous System (CNS) metastases
Primary central nervous system (CNS) lymphoma
Central nervous system (CNS) metastasis
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Has known active central nervous system (CNS) lymphoma
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Active uncontrolled central nervous system (CNS) metastases
Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions).
Patients with current evidence of active central nervous system (CNS) leukemia
Untreated or progressive central nervous system leukemia
Active central nervous system malignancy
Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
Has known active central nervous system (CNS) lymphoma
Rapidly progressive, clinically unstable central nervous system hematological malignancy. Note: Central nervous system evaluation is only required in subjects with known or suspected central nervous system malignancy.
Known central nervous system (CNS) lymphoma
Active, uncontrolled central nervous system (CNS) disease
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Patients with known active uncontrolled central nervous system (CNS) leukemia
Patients with symptomatic, untreated central nervous system (CNS) metastases are not eligible
Persons with uncontrolled central nervous system malignancy
Patients with active central nervous system leukemia or requiring maintenance intrathecal chemotherapy
Patients with untreated brain metastases/central nervous system (CNS) disease will be excluded
Active central nervous system (CNS) malignancy
Untreated central nervous system metastases; patients with a history of brain metastases must have had no central nervous system (CNS)-directed therapy within the past 60 days and radiological assessment within 30 days of study entry demonstrating a lack of progressive CNS disease
About to undergo palliative radiation for a symptomatic central nervous system (CNS) metastasis
Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression; subjects previously treated central nervous system metastases that are radiographically and neurologically stable for at least 6 weeks and do not require corticosteroids (of any dose) for symptomatic management for at least 14 days prior to first dose of MEDI4736 and tremelimumab are permitted to enroll
Eligible for extra-central nervous system (CNS) SAbR to 1-6 sites of disease
Any history of central nervous system (CNS) metastases that is not adequately treated with surgery or SABR > 14 days prior
Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
Symptomatic and refractory central nervous system (CNS) leukemia
Patients with central nervous system (CNS) metastases who are neurologically unstable
Active leukemia in the central nervous system (CNS)
Patients with active central nervous system (CNS) disease or history of brain metastases are excluded from study
Known central nervous system lymphoma
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Central nervous system (CNS) lymphoma
Active central nervous system malignancy
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Patient has central nervous system (CNS) metastases or seizure disorder
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Patients with clinical evidences of active central nervous system (CNS) disease at inclusion
Active central nervous system (CNS) disease
Patients must not have active central nervous system leukemia; patients with history of central nervous system (CNS) leukemia with no evidence of active CNS disease may be enrolled; maintenance intrathecal chemotherapy for adequately treated CNS involvement with leukemia is allowed with approval from the study supporter
Evidence of > grade 1 central nervous system (CNS) hemorrhage or > grade 3 venous thromboembolism
History of central nervous system disease (e.g., seizures) unrelated to cancer unless adequately controlled by medication
Central nervous system (CNS) metastasis
Active meningeal or central nervous system disease
Active central nervous system metastasis and/or carcinomatous meningitis causing symptoms
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.
Participants who have known central nervous system, meningeal, or epidural disease including brain metastases.
Symptomatic untreated metastases in the central nervous system
Patient with active central nervous system (CNS) disease
Has known central nervous system (CNS) metastases and/or carcinomatous meningitis
AND (by central assessment) either:
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy
Patients with carcinomatous meningitis or active central nervous system (CNS) metastases
Active central nervous system leukemia
Patients with a history of central nervous system disease must not have severe peripheral neuropathy, signs of leukencephalopathy, or active central nervous system (CNS) infection; patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsant therapy
Patients may have central nervous system (CNS) metastases which have been treated and are radiographically stable for at least 4 weeks
Known active central nervous system lymphoma
Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
Patients with active central nervous system (CNS) or epidural tumor
Active central nervous system lymphoma
Patients with central nervous system (CNS) disease who have received treatment and disease has been stable for four weeks are eligible
Active central nervous system (CNS) or extramedullary disease
Evidence of central nervous system (CNS) metastases
All patients with central nervous system lymphoma
Active central nervous system (CNS) disease.
Isolated extramedullary relapse (i.e. testicular, central nervous system)
Patients with central nervous system (CNS) tumors who are receiving steroids are eligible
Documented central nervous system metastases or liver metastasis
Active or untreated central nervous system (CNS) metastases
Active and/or untreated central nervous system (CNS) leukemia
Individuals with the presence of symptomatic central nervous system (CNS) metastases requiring radiation treatment, surgery, or ongoing use of corticosteroids
Non-central nervous system (CNS) radiotherapy within 1 week prior to C1D1 of study therapy
Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
No active central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease
Patients may NOT have evidence or symptoms of central nervous system (CNS) disease at the time of enrollment
Clinically active central nervous system leukemia.
Known untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
Previous radiotherapy for central nervous system metastases
Known central nervous system (CNS) metastases requiring treatment, such as surgery, radiation or steroids
Patients with evidence of active central nervous system lymphoma
Known central nervous system lymphoma
Active (symptomatic) central nervous system (CNS) metastasis.
Known chronic or active viral infections of the central nervous system (CNS)
Known cerebral metastases, central nervous system (CNS) or epidural tumor
Presence of untreated and/or symptomatic central nervous system (CNS) metastasis
Confirmed absence of central nervous system (CNS) disease
Active central nervous system (CNS) disease
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Patients with active central nervous system (CNS) disease
Central nervous system (CNS) metastases or seizure disorder
Prior history of encephalitis, multiple sclerosis, or other central nervous system (CNS) infection
No uncontrolled seizure disorder, active neurological disease, or known central nervous system (CNS) disease
Known central nervous system (CNS) lymphoma
Active central nervous system (CNS) leukemia
Known central nervous system (CNS) metastases
Known central nervous system metastasis. Patients with history of central nervous system metastases are eligible if they are clinically or radiographically stable for at least 3 months and not taking steroids or anticonvulsants.
Patients with active central nervous system (CNS) or epidural tumor
Patients with known malignant disease of the central nervous system.
History of primary central nervous system (CNS) disease that would interfere with subject evaluation
Patient with active central nervous system (CNS) disease
Patient has a primary central nervous system tumor
Central nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation
Presence of leukemia in the central nervous system (CNS)
No current central nervous system (CNS) myeloma at time of enrollment
Tumors arising outside of the central nervous system (CNS)
Active central nervous system lymphoma
Symptomatic Central nervous system (CNS) metastases and/or carcinomatous meningitis
Known clinically active central nervous system (CNS) or extramedullary AML, except leukemia cutis.
Any history of disease involving the central nervous system (Part 1). Known active disease involving the central nervous system (Part 2).
Presence of untreated or symptomatic central nervous system metastases, or central nervous system metastases that currently require local therapy (such as radiotherapy or surgery), or require doses of corticosteroids within the prior 4 weeks
Have active central nervous system (CNS) leukemia
Active central nervous system tumor or metastases
Known active central nervous system or leptomeningeal lymphoma
Presence of leukemia in the central nervous system (CNS)
Presence of central nervous system (CNS) disease
Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed
Patients with active central nervous system (CNS) disease, defined as brain or meningeal metastases that are not in complete remission
Active central nervous system malignancy
Active central nervous system (CNS) leukemia at time of HCT
Presence of central nervous system (CNS) metastases
Evidence of active extramedullary disease (including central nervous system [CNS] leukemia)
Active central nervous system (CNS) leukemia at time of HSCT
Active central nervous system malignancy
Patients may have active malignancy outside the central nervous system
Subjects with rapidly progressing central nervous system (CNS) disease with associated neurological deterioration
Known central nervous system brain metastases
Subject has known active central nervous system metastases and/or carcinomatous meningitis.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Symptomatic central nervous system metastases
Patients with central nervous system (CNS) malignancies.
Has known active (growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; prior radiation or resection is acceptable if clinically stable for at least 4 weeks
Active, untreated central nervous system metastases.
Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.
Active central nervous system malignancy
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Active or history of central nervous system (CNS) metastases
Untreated central nervous system (CNS) metastatic disease, leptomeningeal disease, or cord compression
Clinically active central nervous system (CNS) leukemia;
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Symptomatic central nervous system (CNS) metastases who are neurologically unstable
Patients with limited disease (if MF/SS: stages IA) or central nervous system (CNS) disease.
Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma.
History of asymptomatic or symptomatic central nervous system (CNS) metastasis
Evidence of central nervous system (CNS) metastasis (negative imaging study, if clinically indicated, within 4 weeks of Screening Visit).
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Known metastasis to the central nervous system
Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis
Concommitant therapy that includes other chemotherapy that is or may be active against ALL (except central nervous system [CNS] therapy)
Subjects with symptomatic, untreated metastases to the central nervous system (CNS) at the time of screening.
Active central nervous system (CNS) disease
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system leukemia
Known clinically active central nervous system (CNS) leukemia
Known clinically active central nervous system(CNS) leukemia
Primary central nervous system (CNS) lymphoma
Known central nervous system (CNS) lymphoma or leukemia
Patients with known or suspected central nervous system (CNS) leukemia are not eligible
Known active central nervous system metastases and/or carcinomatous meningitis
Any advanced unresectable/stage IV solid tumor with exception of primary central nervous system (CNS) malignancy is permitted.
Evidence of progressive or symptomatic central nervous system (CNS) metastases or leptomeningeal disease
Presence of known, active central nervous system (CNS) metastases
PRE-REGISTRATION: Primary tumors of the central nervous system.
Central nervous system (CNS) metastases including a history of leptomeningeal carcinomatosis
Known untreated central nervous system (CNS) metastases; leptomeningeal disease will be an absolute exclusion criterion due to limited life expectancy
Patients should not have evidence of active central nervous system lymphoma
History of central nervous system (CNS) metastasis.
All patients with central nervous system lymphoma.
Active leukemic central nervous system (CNS) disease
Symptomatic or untreated central nervous system (CNS) metastases
Eligible for extra-central nervous system (CNS) SABR to 1-5 sites of disease
Any history of central nervous system (CNS) metastases that is not adequately treated (surgery or radiation) > 14 days prior to registration
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Patients with isolated extramedullary disease or with parenchymal central nervous system (CNS) disease
Patients with known central nervous system infiltration with leukemia
Untreated brain metastases or neurologically unstable central nervous system (CNS) metastases
Have clinical symptoms suggestive of active central nervous system (CNS) leukemia or known CNS leukemia.
Patients with symptomatic central nervous system (CNS) metastases.
Presence of symptomatic central nervous system (CNS) metastases
Patients with isolated central nervous system (CNS), testicular, or other extramedullary site of relapse
Subject has known current central nervous system (CNS) disease
Central nervous system (CNS) metastases or seizure disorder
Pre-existing central nervous system (CNS) demyelination or seizure disorders
Subjects must not have evidence of active leukemia in the central nervous system (CNS)
Symptomatic central nervous system (CNS) metastases requiring treatment
Active central nervous system (CNS) leukemia
Central nervous system (CNS) toxicity =< grade 2
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
Patients with active central nervous system (CNS) malignancy
Symptomatic central nervous system (CNS) metastasis.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may not participate
Known central nervous system metastases
Patients must not have known active central nervous system (CNS) metastases; patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy, and stable with no recurrent lesions for at least 6 months
Distant metastatic disease including central nervous system (CNS) or leptomeningeal metastases is not allowed
Uncontrolled central nervous system metastases
Uncontrolled central nervous system metastases; treated, non-progressing central nervous system (CNS) disease (documented by brain magnetic resonance imaging [MRI]) off corticosteroids for at least 1 month are eligible
Patients with known metastasis of malignant plasma cells to the central nervous system (if not suspected no specific testing is required)
Patient has chronic or active viral infections of the central nervous system (CNS)
Patients with disease progression in the central nervous system (CNS) only
Patients with suspected or proven central nervous system (CNS) leukemia; (diagnostic lumbar puncture not required before enrollment)
Patients with active central nervous system (CNS) or epidural tumor
Lymphoma involving the central nervous system
Patients with active central nervous system (CNS) metastases
Known central nervous system (CNS) metastases with active symptoms, or requiring anticonvulsive medications, or steroids
Active or suspicion of central nervous system (CNS) leukemia
History of central nervous system (CNS) disease
Central nervous system disease as evidence by clinical symptomatology
Lymphoma involving the central nervous system
Central nervous system (CNS) metastases that are symptomatic and/or requiring steroids
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Subject has clinically active central nervous system leukemia.
Patients with known central nervous system (CNS) metastases must have stable disease off steroids after treatment with surgery or radiation therapy
Has known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis.
Subjects with known central nervous system disease
Active, untreated central nervous system metastases.
No brain or central nervous system (CNS) metastases
Has known active central nervous system metastases and/or carcinomatous meningitis.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Untreated or symptomatic central nervous system (CNS) metastases
Active Central nervous system (CNS) metastases
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
known central nervous system (CNS) metastases that are untreated, symptomatic, or require steroids to control symptoms
Known active or untreated central nervous system (CNS) metastases. - Pregnant, planning to become pregnant within 6 months of treatment, or nursing.
Patient must have no prior history or current clinically apparent central nervous system metastases
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
Known central nervous system (CNS) lymphomas; Active cerebral/meningeal disease related to the underlying malignancy
Subject has symptomatic and untreated central nervous system (CNS) disease
Known and untreated brain metastases. Patients with primary CNS (central nervous system) malignancies are excluded.
Known central nervous system metastases or central nervous system as the only source of disease
Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of PD 0332991
Presence of or known history of brain/central nervous system (CNS) tumor or metastases
Known and untreated, or active central nervous system (CNS) metastases (progressing or requiring treatment)
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Primary disease involving the Central Nervous System (CNS)
Known active central nervous system metastases and/or carcinomatous meningitis.
Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of central nervous system metastatic disease, have been off glucocorticoids for at least 4 weeks, have no overt evidence of neurological deficit and are ? 6 weeks from completion of brain irradiation.
Active central nervous system disease.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Known central nervous system metastases or central nervous system as the only source of disease
At the time of Day 1 of the study, subjects with central nervous system (CNS) metastases must have been treated and must be asymptomatic
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
Clinically active primary central nervous system tumors or brain metastases with the exception of subjects with glioblastoma multiform that carry ROS1 rearrangement
Known symptomatic central nervous system (CNS) metastases
Uncontrolled central nervous system metastases
Known history of central nervous system metastasis
Known active central nervous system or leptomeningeal lymphoma
Proven Central Nervous System (CNS) leukemia
Symptomatic leukoencephalopathy, active central nervous system (CNS) malignancy or other neuropsychiatric abnormalities believed to preclude transplantation
Has active central nervous system (CNS) or leptomeningeal metastasis
Have symptomatic central nervous system metastasis. Screening of asymptomatic participants is not required for enrollment.
Participant has untreated central nervous system (CNS) metastases.
Participants with known central nervous system disease
Has known active central nervous system metastases
Active central nervous system metastases and/or carcinomatous meningitis
Untreated or active/progressing Central Nervous system (CNS) metastases
Central nervous system metastasis
Patients are ineligible if they have any history of central nervous system (CNS) metastases
Have symptomatic or non stable central nervous system (CNS) malignancy.
Current or past history of central nervous system lymphoma
History of or active central nervous system (CNS) malignancy
Patients with primary central nervous system (CNS) lymphoma
Known brain or central nervous system metastases or history of uncontrolled seizures.
Has a history of known central nervous system metastasis
Central nervous system lymphoma or leptomeningeal infiltration
No untreated central nervous system metastases, or if treated must be neurologically stable for at least 2 weeks prior to enrollment
Individuals with known or suspected central nervous system metastases or individuals requiring chronic daily treatment with oral corticosteroids
Known untreated or active central nervous system (CNS) metastases
Carcinomatous meningitis and/or symptomatic central nervous system (CNS) metastases.
Known central nervous system lymphoma
Active central nervous system (CNS) metastases and/or carcinomatous meningitis
Subject has uncontrolled metastases to the central nervous system (CNS).
Active/symptoms of central nervous system (CNS) disease
Patients with known active uncontrolled central nervous system (CNS) leukemia.
Symptomatic central nervous system metastases (excluding Glioblastoma multiforrme (GBM) and Primary Central Nervous System Lymphoma (PCNSL). Subjects with brain metastases that have been previously treated and are stable for 6 weeks are allowed.
Evidence for central nervous system (CNS) metastatic disease
Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study
Known active central nervous system metastases and/or carcinomatous meningitis.
Subjects with active central nervous system metastases
Known active central nervous system lymphoma or leptomeningeal disease
Known or suspected central nervous system metastases
Active central nervous system (CNS) metastases requiring treatment
Central nervous system (CNS) metastasis.
Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available
Has radiographically detectable central nervous system (CNS) metastases and/or carcinomatous meningitis
Symptomatic or untreated central nervous system metastases requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids; if treated, patient must be asymptomatic for 3 months prior to study entry.
Central nervous system lymphoma or leptomeningeal infiltration
Primary central nervous system (CNS) malignancy or active metastases within 5 years
Have the presence of unstable central nervous system (CNS) metastasis.
Have symptomatic central nervous system (CNS) malignancy or metastasis (screening not required).
Active or untreated central nervous system (CNS) metastasis
Have confirmed presence of central nervous system metastases
Known central nervous system metastases and/or carcinomatous meningitis
Patients with untreated or symptomatic central nervous system (CNS) metastases
Evidence of active central nervous system (CNS) leukemia
Patient has active or history of central nervous system (CNS) disease
Have clinical evidence or a history of central nervous system (CNS) metastasis
Patients with known central nervous system metastases.
Active central nervous system (CNS) metastases
Known untreated central nervous system (CNS) metastasis
Patients with brain metastases must have at least one site of measurable disease outside of the central nervous system
Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
Symptomatic Central Nervous System (CNS) metastasis
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Parts A, B, D and E: Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
Subjects with active central nervous system (CNS) metastases are excluded
Participants with central nervous system (CNS) lymphoma
Untreated or symptomatic central nervous system metastases.
Lymphoma involving the central nervous system
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Adequate central nervous system function defined as:\r\n* Patients with a history of central nervous system (CNS) disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment\r\n* Patients with seizure disorders may be enrolled if seizures are well controlled on anticonvulsants\r\n* CNS toxicity =< grade 2
Phase 1b: History or evidence of central nervous system (CNS) metastases
Patients with active/uncontrolled central nervous system (CNS) leukemia
Active central nervous system (CNS) disease at the time of treatment
Active central nervous system (CNS) or symptomatic epidural metastatic disease
History of central nervous system metastasis.
Central nervous system (CNS) metastases or seizure disorder
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Symptomatic and/or untreated central nervous system metastases
Active central nervous system metastases and/or carcinomatous meningitis
Central nervous system metastases
Known central nervous system lymphoma (either primary or metastatic).
Subject has clinically active central nervous system leukemia.
Patients with known central nervous system, meningeal, or epidural disease.
Active central nervous system (CNS) leukemia or known CNS leukemia.
History of central nervous system (CNS) lymphoma or other CNS disease
Patients with a history of symptomatic central nervous system metastases, unless treated and asymptomatic
Patients with active central nervous system (CNS) disease defined as symptomatic meningeal lymphoma or known CNS parenchymal lymphoma
Central nervous system (CNS) leukemia
Central nervous system (CNS) metastasis
Active central nervous system (CNS) metastases.
Have clinical evidence or history of central nervous system metastasis.
Known cytopathologically confirmed central nervous system (CNS) infiltration
Known central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system (CNS) lymphoma
Current central nervous systemic disease
Clinically apparent central nervous system metastases or carcinomatous meningitis
Presence of known central nervous system or brain metastases
Known central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system metastases and/or carcinomatous meningitis.
Known central nervous system lymphoma or leptomeningeal disease, except subjects with a history of central nervous system lymphoma treated and in remission > 6 months
No active central nervous system (CNS) disease
Untreated or symptomatic central nervous system (CNS) metastases
Known active central nervous system metastases and/or carcinomatous meningitis.
Known central nervous system metastases and/or carcinomatous meningitis
Known central nervous system metastases and/or carcinomatous meningitis
Known central nervous system (CNS) lymphoma
Subjects with active cancer that has spread to the central nervous system
Symptomatic central nervous system (CNS) malignancy or metastasis.
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system (CNS) metastases and/or carcinomatous meningitis
Active central nervous system metastases and/or carcinomatous meningitis
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Patients with central nervous system (CNS) tumors or known brain metastases
Known or suspected brain or central nervous system (CNS) metastases, or carcinomatous meningitis
Has known active central nervous system disease and/or carcinomatous meningitis
All patients with central nervous system lymphoma
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Active central nervous system (CNS) metastases and/or carcinomatous meningitis
Other serious diseases (hematological, hepatic, renal, respiratory, central nervous system, autoimmune or psychiatric)
Any history of or current central nervous system (CNS) metastases. Baseline imaging of the brain is required within 28 days prior to randomization
Untreated central nervous system metastatic disease l
Prior or concurrent central nervous system (CNS) metastases
Known central nervous system (CNS) disease
Presence of symptomatic or uncontrolled brain or central nervous system metastases
Active uncontrolled central nervous system (CNS) leukemia; NOTE: positive (cyto)pathology is allowed and patient can receive intrathecal chemotherapy
Central nervous system (CNS) metastases may be permitted but must be treated and neurologically stable
Have clinical evidence or history of central nervous system metastasis
Patients with active (untreated or relapsed) central nervous system (CNS) metastasis of the patient’s myeloma
History of central nervous system (CNS) metastasis that are untreated or not stable
Patients with known active central nervous system (CNS) disease
Untreated central nervous system (CNS) metastases
Known central nervous system lymphoma
Known central nervous system (CNS) lymphoma
Patient has central nervous system leukemia
Central nervous system (CNS) metastases
Central nervous system (CNS) disease, including treated brain metastases
Central nervous system (CNS) metastases
Clinical evidence of active central nervous system (CNS) leukemia
Known central nervous system lymphoma or leukemia; subjects with symptoms of CNS disease must have a negative CT scan or negative diagnostic lumbar puncture prior to randomization
Known active or untreated central nervous system (CNS) metastases
History of central nervous system (CNS) thrombotic/embolic or ischemic event(s)
Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
Known central nervous system lymphoma
Subject has clinically active central nervous system leukemia.
Asymptomatic, central nervous system metastases are permitted
Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis
Clinical evidence of active central nervous system leukemia at the time of screening
Phase 1: All solid tumors (measurable or evaluable disease), including primary central nervous system (CNS) tumors; exclusion of hepatoblastoma and lymphomas
No known central nervous system (CNS) metastases
Patients with untreated central nervous system (CNS) or epidural tumor
Known history of central nervous system (CNS) metastases
Any untreated central nervous system (CNS) lesion
Symptomatic central nervous system (CNS) NHL.
Symptomatic central nervous system (CNS) disease.
Known central nervous system or primary mediastinal lymphoma
Known active central nervous system (CNS) malignancy
Previous radiotherapy for cerebral metastases, central nervous system (CNS) or epidural tumor
Known brain metastases or primary central nervous system tumors with seizures that are not well controlled with standard medical therapy
Presence of untreated/active central nervous system (CNS) metastases
Patients with either clinically apparent central nervous system metastases or carcinomatous meningitis are ineligible
Known cytopathologically confirmed central nervous system (CNS) infiltration
The patient has either clinically apparent central nervous system metastases or carcinomatous meningitis
Clinically unstable central nervous system (CNS) metastasis
Significant co-morbid central nervous system disease, including but not limited to, multiple sclerosis
All patients with history of central nervous system lymphoma
Clinical evidence of central nervous system (CNS) metastasis.
Patient must not have a history of or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have had previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medications (with the exception of Keppra) for 1 month prior to first dose of pazopanib
Symptomatic or untreated central nervous system (CNS) metastases requiring concurrent treatment
Patient must not have known central nervous system (CNS) leukemia
History or clinical evidence of central nervous system (CNS), meningeal, or epidural disease, including brain metastasis.
Active central nervous system (CNS) leukemia
Central nervous system metastases unless: (1) metastases have been treated and have remained controlled for at least two weeks following treatment, AND (2) patient has no residual neurological dysfunction off corticosteroids for at least one week; a CT or MRI to evaluate for central nervous system (CNS) disease is required for symptomatic patients only
Have malignancy or metastasis of the central nervous system
Hematologic and primary central nervous system (CNS) malignancies
Known clinically active central nervous system (CNS) leukemia
Any primary or active central nervous system (CNS) malignancy, including metastatic disease
Known central nervous system leukemia/lymphoma or Richter's transformation
Presence of leukemia in the central nervous system (CNS)
Known active Central Nervous System (CNS) lymphoma.
Patients with active and/or untreated central nervous system (CNS) leukemia will not be eligible
Known central nervous system (CNS) metastases
Known or suspected brain or other central nervous system (CNS) metastases
Active central nervous system (CNS) metastases
Active or prior central nervous system (CNS) leukemia, unless in complete remission for at least 3 months
Central nervous system function defined as not severely somnolent or comatose (central cortical neurotoxicity scale < grade 3)
Presence of central nervous system (CNS) metastatic disease
History of demyelinating disease or inflammatory disease of the central nervous system or the peripheral nervous system
Patients with primary central nervous system tumors or brain metastases.
Active central nervous system (CNS) malignancy; however, patients with a history of positive Cerebrospinal fluid (CSF) cytology that has become negative with intrathecal chemotherapy are eligible.
History or clinical evidence of central nervous system metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated central nervous system (CNS) metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 2 months prior to first dose of study drug
For Dose Escalation (Part A): Have central nervous system (CNS) malignancy or metastasis
Pathology from the resected brain metastasis must be consistent with a non-central nervous system primary site; Note: patients with or without active disease outside the nervous system are eligible (including patients with unknown primaries), as long as the pathology from the brain is consistent with a non-central nervous system primary site
Active central nervous system (CNS) disease
Patients with stable, treated central nervous system (CNS) disease are eligible
Active central nervous system (CNS) leukemia at time of treatment
Patients with central nervous system (CNS) metastases are eligible (as long as projected survival is > 6 months)
Have active Central Nervous System (CNS) disease
Primary central nervous system (CNS) lymphoma
Has active or untreated brain or central nervous system metastases.
Has known active central nervous system metastases and/or carcinomatous meningitis.
History of central nervous system lymphoma (either primary or metastatic) or leptomeningeal disease.
Active or history of central nervous system metastases.
Patients with history or known presence of primary central nervous system (CNS) tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded
Medically apparent central nervous system lymphoma or leptomeningeal disease
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Central nervous system lymphoma or leptomeningeal disease
Subjects with symptomatic central nervous system (CNS) metastases
Known central nervous system metastasis
Active central nervous system (CNS) lymphoma
Active central nervous system (CNS) leukemia
Active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids)
Patients with relapse also detected in the central nervous system (CNS) may be treated on this protocol; however, if intrathecal chemotherapy is being administered, T cells should not be administered until at least 24 hours thereafter
Patients with brain or central nervous system metastases, including leptomeningeal disease
Active central nervous system (CNS) disease in patient with history of CNS malignancy
History or clinically suspicious for cancer-related Central Nervous System disease
Patient have uncontrolled brain metastases or central nervous system disease.
Patients may have active malignancy outside the central nervous system
Active central nervous system metastases
Known central nervous system lymphoma
History or known presence of central nervous system (CNS) metastases
Central Nervous System (CNS) disease only.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known central nervous system malignancy.
Active central nervous system (CNS) disease
Active central nervous system (CNS) or extramedullary malignant disease
Active, symptomatic central nervous system (CNS) leukemia;
Patients with history of central nervous system (CNS) metastasis may not be enrolled on the study, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
Patients with known active central nervous system (CNS) leukemia
Previous central nervous system leukemia
Known central nervous system (CNS) metastases and/or carcinomatous meningitis.
Known central nervous system metastasis that is unstable within the last 2 months
History of lymphoma involving the central nervous system
Known central nervous system metastases
Patients with symptomatic central nervous system (CNS) leukemia or patients with poorly controlled central nervous system leukemia
Patients with central nervous system (CNS) disease or testicular disease are eligible
Active, untreated central nervous system metastases.
Active, untreated central nervous system metastases.
Active central nervous system (CNS) leukemia
Known active central nervous system (CNS) leukemia.
Patients with symptomatic central nervous system (CNS) metastases
Active central nervous system disease (CNS) metastases, as indicated by clinical symptoms, cerebral edema or progressive growth
Known central nervous system (CNS) lymphoma
Central nervous system (CNS) lymphoma
Have active central nervous system (CNS) metastasis
Known cerebral metastases, central nervous system (CNS) or epidural tumor
Central nervous system (CNS): no recent history (within 6 month) of cerebrovascular accident, transient ischemic attacks, central nervous system or brain metastases
Uncontrolled central nervous system (CNS) disease
Known active central nervous system (CNS) metastases.
Patients with known active central nervous system (CNS) leukemia will be excluded from this clinical study
Known or suspected brain or central nervous system metastases
Known central nervous system (CNS) disease
Known active leukemia of the central nervous system
All patients with active central nervous system lymphoma
Known central nervous system metastases
Metastatic disease to the central nervous system for which other therapeutic options, including radiotherapy, may be available.
Active or untreated central nervous system (CNS) metastases
Active or untreated central nervous system (CNS) lesions
Symptomatic central nervous system metastases or lesions requiring treatment.
Patients with active central nervous system (CNS) malignancy are not eligible for this trial
Subjects with active or symptomatic central nervous system metastases are excluded. Subjects with central nervous system metastases are eligible for the study if the metastases have been treated by surgery and/or radiation therapy, the subject is off corticosteroids for at least 2 weeks and the subject is neurologically stable
Active/symptoms of central nervous system (CNS) disease
Central nervous system (CNS) disease
Patients with known symptomatic central nervous system (CNS) metastases requiring steroids
Central nervous system metastasis
Central nervous system metastases
Untreated central nervous system (CNS) metastatic disease
Presence of clinically apparent untreated central nervous system metastases.
Presence of central nervous system (CNS) leukemia.
Patients are excluded if they have a history of central nervous system (CNS) metastases
Untreated brain or central nervous system (CNS) metastases
Untreated central nervous system metastases
Central nervous system (CNS) metastases or seizure disorder
Central Nervous System (CNS) Lymphoma or chronic immunosuppression-associated central nervous system (CNS) lymphoma.
Patients with known central nervous system metastasis are not eligible
Active or untreated central nervous system (CNS) metastases
Symptomatic central nervous system disease, malignancy, or metastasis
Primary brain or other central nervous system malignancy.
History of central nervous system hemorrhage
Known central nervous system (CNS) or brain metastases.
Medically apparent central nervous system lymphoma or leptomeningeal disease
Primary central nervous system (CNS) lymphoma
Active or untreated central nervous system (CNS) metastases
Known central nervous system (CNS) disease, other than stable, treated brain metastases
Active central nervous system (CNS) disease in patient with history of CNS malignancy
Central nervous system or leptomeningeal lymphoma
Subjects with known central nervous system (CNS) disease are not eligible, except for those subjects with treated brain metastasis.
Known presence of central nervous system metastases
Evidence of central nervous system metastasis
Patients with documented central nervous system (CNS) disease
Central nervous system metastases
Any history or signs of central nervous system metastases;
Known untreated central nervous system (CNS) metastasis
Primary central nervous system (CNS) lymphoma
Known central nervous system (CNS) disease except for treated brain metastasis
Symptomatic and/or untreated central nervous system metastases
Has a history of primary central nervous system malignancy.
Evidence of central nervous system (CNS) metastasis who have not received prior definitive therapy for their lesions.
Patient has no worsening central nervous system symptoms; and
Symptomatic or untreated central nervous system metastases requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids; if treated, subject must be asymptomatic for 3 months prior to study entry
Subject has clinically active central nervous system leukemia
Untreated or active central nervous system (CNS) metastases.
Subjects with asymptomatic brain metastases or other central nervous system (CNS) disease at screening/diagnosis are eligible
Untreated central nervous system metastases
Symptomatic central nervous system (CNS) metastases requiring steroid use
Untreated/active central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control)
Patients with active central nervous system (CNS) disease
Evidence of central nervous system lymphoma or lymphomatous meningitis
Known central nervous system disease (e.g., Alzheimer's disease).
Patients with a history of central nervous system (CNS) malignancy.
Patients with central nervous system disease
Current evidence of central nervous system (CNS) leukemia
CNS (Central Nervous System) tumors as well as history of brain metastases
Known brain tumors or Central nervous system (CNS) metastases
Has a symptomatic central nervous system (CNS) tumor causing nausea and/or vomiting
Patient has active or history of central nervous system (CNS) disease.
Current uncontrolled central nervous system (CNS) metastasis or malignant brain tumors
Patients with history or known presence of primary central nervous system (CNS) tumors, seizures not well-controlled with standard medical therapy, or history of stroke will also be excluded
Untreated or active brain metastases or central nervous system cancer, as defined per protocol
History of central nervous system (CNS) PTLD
Active central nervous system tumors or metastases
Known active central nervous system metastases and/or carcinomatous meningitis.
Patients with symptomatic central nervous system (CNS) metastases must have stable disease after treatment with surgery or radiation therapy
Patients with Central Nervous System (CNS) metastasis which are: symptomatic or require treatment for symptom control and/or growing
Radiographic evidence of central nervous system metastases that are not well controlled with local therapy (irradiation or surgery)
Active Central Nervous System [CNS] disease
History or presence of known central nervous system metastases
Known central nervous system, meningeal or epidural disease including brain metastases
Known primary central nervous system (CNS) tumors or brain metastases
Known central nervous system (CNS) disease except for treated brain metastases
Untreated or active cerebral nervous system metastases
Patients with active central nervous system (CNS) lymphoma
Symptomatic Central Nervous System (CNS) metastases
Known untreated or active central nervous system (CNS) metastases
Stage IV patients are considered provided they have a single non-central nervous system (CNS) metastasis (that is amenable to treatment with radiation therapy)
Active central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease or history of brain metastases (mets) are excluded from study
Untreated or active central nervous system (CNS) metastases
Known central nervous system metastasis
Subjects with known central nervous system metastases.
Symptomatic central nervous system malignancy or metastasis (screening not required).
Have symptomatic central nervous system (CNS) malignancy or metastasis
Central nervous system (CNS) metastases from lymphoma or small cell lung cancer
Primary central nervous system (CNS) malignancy or untreated/active CNS metastases
b. Central nervous system (CNS) trauma or active seizure disorders requiring medication
Primary malignancy of the central nervous system.
Patients with active central nervous system (CNS) disease
History of Central nervous system (CNS) or brain metastases
Patients with history of central nervous system (CNS) metastasis, unless control has been achieved with either radiation or surgical resection at least 3 months prior to enrollment on study
Uncontrolled central nervous system metastases
No evidence of central nervous system (CNS) metastases
Active untreated central nervous system (CNS) metastasis
Central nervous system tumors are allowed
Known central nervous system (CNS) lymphoma, leptomeningeal lymphoma
Untreated central nervous system (CNS) metastases.
Known central nervous system metastasis
Known central nervous system lymphoma
Active Central Nervous System (CNS) metastases or carcinomatous meningitis
Unstable metastases to the central nervous system (CNS)
Metastatic disease to the central nervous system
Active MM involving the central nervous system.
Pre-existing central nervous system (CNS) demyelination or seizure disorders
Active MM involving the central nervous system (CNS).
Patients with symptomatic Central Nervous System (CNS) metastases
Active central nervous system lesions
Active central nervous system (CNS) leukemia or known chloromatous disease
Active central nervous system (CNS) disease (related to primary malignancy) at the time of enrollment
Evidence of central nervous system metastasis and have not received prior definitive therapy for their lesions.
Central nervous system (CNS) lymphoma; active brain or leptomeningeal metastases.
Central nervous system (CNS) disease that is untreated, symptomatic, or requires therapy to control symptoms.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Known and untreated, or active central nervous system metastases
Participants with central nervous system (CNS) (e.g., brain or leptomeningeal) metastases.
Has known active (= growing) central nervous system (CNS) metastases and/or carcinomatous meningitis; radiation or resected brain metastasis are acceptable if clinically stable
Known central nervous system metastases or central nervous system as the only source of disease
Known or suspected brain or other central nervous system metastases
History of significant central nervous system (CNS) injury or disease predating or unrelated to cancer diagnosis
Patient has symptomatic primary or metastatic central nervous system (CNS) disease
Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy
Active central nervous system (CNS) leukemia
Patients with history of seizures or uncontrolled central nervous system (CNS) disease, significant hepatic or renal dysfunction
Diagnosis of primary central nervous system (CNS) lymphoma
Patients with active central nervous system (CNS) disease, such as clinically-evident metastases or leptomeningeal disease, dementia, or encephalopathy.
Known brain metastasis or primary central nervous system (CNS) malignancy
History of central nervous system (CNS) tumor
Known primary central nervous system (CNS) malignancy or untreated or active CNS metastases
Known central nervous system (CNS) lymphoma
Cranial radiotherapy for central nervous system (CNS) leukostasis;
History of Grade >= 2 central nervous system (CNS) hemorrhage
Known central nervous system (CNS) lymphoma
Presence of symptomatic central nervous system metastases.
Uncontrolled Central Nervous System (CNS) metastases
Subjects with untreated Central nervous system (CNS) metastases are excluded
Have known central nervous system metastasis or Central Nervous System lymphoma;
All patients need to have received at least one prior central nervous system (CNS) directed therapy; there is no restriction on the number of recurrences
Participant is currently receiving treatment with benzodiazepines or other central nervous system (CNS) depressants
Active central nervous system (CNS) disease
Overt central nervous system manifestations of leukemia at diagnosis
Active central nervous system (CNS) disease (the action for acupuncture may be associated with central nervous system activity, and patients with CNS pathology may respond differently to treatment than the general population)
Uncontrolled central nervous system (CNS) disease (for hematologic malignancies)
Active central nervous system malignancy
Symptomatic, untreated or unstable central nervous system or leptomeningeal metastases
Non-central nervous system (CNS) malignant disease must be sufficiently controlled so that patient can be without additional systemic therapy for approximately 2 months
Known metastases to the central nervous system
Subjects with known central nervous system disease
Subject has a history of central nervous system radiotherapy that encompasses all or part of the cochlea or will receive such radiation therapy during the course of the study.
Has a symptomatic primary or metastatic central nervous system (CNS) malignancy with nausea and/or vomiting (asymptomatic participants may participate in study)
Patient must not have untreated or symptomatic central nervous system (CNS) metastasis
Central nervous system (CNS) only disease on recent imaging
Patients with a known diagnosis of central nervous system (CNS) malignancy, including metastases, with known enhancement on magnetic resonance (MR) who are otherwise eligible to undergo MRI
Active, untreated central nervous system metastases.
History or current evidence of central nervous system lymphoma
MM involving the central nervous system.
Central nervous system (CNS) metastases
Patients with a history of symptomatic central nervous system (CNS) unless they have been treated and are asymptomatic.
Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
Subject has clinically active central nervous system leukemia.
Subject must have either radiological or established histological diagnosis of the following general categories: \r\n* High-grade glioma/central nervous system (CNS) lymphoma or \r\n* Brain metastases
Known active or suspected central nervous system (CNS) leukemia.
Have symptomatic central nervous system (CNS) malignancy or metastasis.
Criteria 6, Active or untreated central nervous system (CNS) metastases per CT or MRI evaluation during screening
Diagnosis: Must have MRI documenting a measurable lesion w/in central nervous system consistent with primary central nervous system tumor, for which maximal safe surgical resection is indicated
Suspected central nervous system (CNS) tumor(s) or sarcoma.
Subjects with symptomatic brain metastasis or central nervous system (CNS) disease
History of primary central nervous system lymphoma or neoplastic central nervous system disease
Patients with active central nervous system leukemia are excluded from this clinical trial; patients with a history of central nervous system (CNS) leukemia but no active disease at the time of enrollment are eligible; the absence of CNS disease must be confirmed by flow cytometric and cytologic examination of the cerebrospinal fluid (CSF) within 7 days of study enrollment
Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
Known active central nervous system (CNS) leukemia.
Known central nervous system (CNS) lymphoma or leukemia
